Avadel Pharmaceuticals plc

NasdaqGM AVDL

Avadel Pharmaceuticals plc Shares (Diluted, Weighted) for the year ending December 31, 2023: 80,174,000

Avadel Pharmaceuticals plc Shares (Diluted, Weighted) is 80,174,000 for the year ending December 31, 2023, a 33.41% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Avadel Pharmaceuticals plc Shares (Diluted, Weighted) for the year ending December 31, 2022 was 60,094,000, a 2.66% change year over year.
Avadel Pharmaceuticals plc Shares (Diluted, Weighted) for the year ending December 31, 2021 was 58,535,000, a 6.54% change year over year.
Avadel Pharmaceuticals plc Shares (Diluted, Weighted) for the year ending December 31, 2020 was 54,941,000, a 46.89% change year over year.
Avadel Pharmaceuticals plc Shares (Diluted, Weighted) for the year ending December 31, 2019 was 37,403,000, a 0.21% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqGM: AVDL

Avadel Pharmaceuticals plc

CEO	Mr. Gregory J. Divis Jr.
IPO Date	June 7, 1996
Location	Ireland
Headquarters	10 Earlsfort Terrace
Employees	154
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key trends

Past 5 years